Sight Sciences announces publication of data on TearCare system

Sight Sciences announced Clinical Ophthalmology has published data from a subgroup analysis of the OLYMPIA trial, which showed a single treatment with the TearCare System led to superior symptoms relief across the following primary symptoms endpoints compared to a LipiFlow application in patients with more severe forms of DED due to meibomian gland dysfunction, MGD. The OLYMPIA study was a multicenter, masked, randomized controlled trial in which 235 participants received either a single TearCare treatment or a single LipiFlow treatment and were followed for one-month post-treatment. Signs and symptoms were assessed across widely accepted endpoints, including the Ocular Surface Disease Index, Symptom Assessment in Dry Eye, Tear Breakup Time and Eye Dryness questionnaires at baseline and at one month. At one month, both treatments demonstrated a statistically significant improvement in all primary and secondary endpoints. "We are encouraged by the superior clinical findings in this subgroup analysis of advanced dry eye patients from the OLYMPIA trial," said Paul Badawi, CEO of Sight Sciences. "TearCare's intuitive design enables clinicians to thoroughly and comprehensively address the root causes of the signs and symptoms of dry eye due to MGD and these data further confirm our confidence in the clinical and economic value that TearCare brings to patients, providers and payors. On the heels of the publication of this superior symptoms data from OLYMPIA, we also announced the completion of patient enrollment in Sahara, our second major RCT where we are comparing TearCare to the standard of care in dry eye, Restasis. We look forward to the readout of TearCare vs Restasis in the summer of 2023."